ALGS - CIK 0001799448
The table below shows Aligos Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$82.50M | -$80.74M | -$79.00M | -$79.39M | -$115.66M | -$74.26M |
| Capital expenditure | - | $130.00K | $19.00K | $943.00K | $892.00K | $2.06M |
| Investing cash flow | -$37.83M | -$18.28M | $44.98M | -$26.29M | $3.02M | $32.76M |
| Dividends paid | - | - | - | - | - |
Aligos Therapeutics, Inc. reported operating cash flow of -$82.50M for fiscal year 2025. That is down 2.2% from -$80.74M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$46.77M (FY 2019) to -$82.50M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $101.64M | $355.00K | $88.33M | $164.00K | $78.68M | $192.35M |